Valneva (NASDAQ:VALN) Stock Price Up 2.3% – Should You Buy?

Valneva SE (NASDAQ:VALN)’s share price was up 2.3% during mid-day trading on Friday . The stock traded as high as $7.45 and last traded at $7.42. Approximately 6,542 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 25,882 shares. The stock had previously closed at $7.25.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $17.00 target price on shares of Valneva in a report on Friday.

Valneva Stock Down 0.1 %

The company’s fifty day moving average price is $6.29 and its 200-day moving average price is $5.61. The stock has a market cap of $588.74 million, a P/E ratio of -55.74 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78.

Valneva (NASDAQ:VALN) last released its earnings results on Thursday, March 20th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.32). The firm had revenue of $56.48 million during the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. Equities analysts forecast that Valneva SE will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. Wells Fargo & Company MN increased its stake in Valneva SE (NASDAQ:VALN) by 14.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 246,766 shares of the company’s stock after buying an additional 30,859 shares during the period. Wells Fargo & Company MN owned 0.30% of Valneva worth $1,079,000 as of its most recent SEC filing. Institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.